About: British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
Creator	Lamb, Christopher Appleby, Richard Arnott, Ian Beattie, R Bloom, Stuart Jones, Gareth-Rhys Kennedy, Nicholas
source	Medline; PMC
abstract	The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government’s advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1136/gutjnl-2020-321244
bibo:pmid	32303607
has license	cc-by-nc
sha1sum (hex)	545de1ca163fe50ed92a46419f0d8a2f8c1a5f85
schema:url	https://doi.org/10.1136/gutjnl-2020-321244
resource representing a document's title	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
has PubMed Central identifier	PMC7211081
has PubMed identifier	32303607
schema:publication	Gut
resource representing a document's body	covid:545de1ca163fe50ed92a46419f0d8a2f8c1a5f85#body_text
is schema:about of	named entity 'clinical care' named entity 'enteral nutrition' named entity 'IBD' named entity 'NHS' named entity 'secondary care' named entity 'general population' named entity 'COVID-19 pandemic' named entity 'steroids' named entity 'IBD' named entity 'blood tests' named entity 'IBD' named entity 'self-isolation' named entity 'adverse outcome' named entity 'Simple Clinical Colitis Activity Index' named entity 'National Health Service' named entity 'azathioprine' named entity 'community acquired pneumonia' named entity 'primary care' named entity 'Coronavirus' named entity 'clinician' named entity 'covid-19' named entity 'subcutaneous' named entity 'hand washing' named entity 'IBD' named entity 'social distancing' named entity 'COVID-19 disease' named entity 'fever' named entity 'research and development' named entity 'injectable' named entity 'healthcare systems' named entity 'pregnancy' named entity 'Hubei' named entity 'telemedicine' named entity 'IBD' named entity 'IBD' named entity 'hypertension' named entity 'COVID' named entity 'infection' named entity 'Colitis' named entity 'IBD' named entity 'clinical decision making' named entity 'placebo' named entity 'biologics' named entity '95% CI' named entity 'calprotectin' named entity 'IBD' named entity 'prednisolone' named entity 'inpatient care' named entity 'clinician' named entity 'IBD' named entity 'comorbidity' named entity 'Inflammatory bowel disease' named entity 'accident and emergency department' named entity 'inflammation' named entity 'coronavirus' named entity 'TNF' named entity 'SARS-CoV-2' named entity 'Ulcerative Colitis' named entity 'COVID-19' named entity 'older age' named entity 'ulcerative colitis' named entity 'biologics' named entity 'COVID' named entity 'adalimumab' named entity 'biologics' named entity 'IBD' named entity 'coronavirus pandemic' named entity 'biomarkers' named entity 'IBD' named entity 'infection' named entity 'steroids' named entity 'steroids' named entity 'non-steroidal anti-inflammatory drugs' named entity 'secondary care' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software